Combination Vaccination With Tetanus Toxoid and Enhanced Tumor-Cell Based Vaccine Against Cervical Cancer in a Mouse Model

Alson, Donia; Schuyler, Scott C.; Yan, Bo Xin; Samimuthu, Karthika; Qiu, Jian Tai

doi:10.3389/fimmu.2020.00927

Cited by 7 publications

(3 citation statements)

References 41 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Enhanced expression of immunostimulators in tumor vaccines is crucial to promote the effectiveness of whole-cell tumor vaccines; using genetic engineering techniques to modify cells to secrete more immunostimulatory factors is a convenient way to achieve this. GVAX is a genetically engineered vaccine that uses tumor cells modified to express GM-CSF, which are used as immune adjuvants and can increase the antigen-presenting capacity of DCs and promote DC survival [ [76] , [77] , [78] ]. One approach for immunotherapy of pancreatic cancer combined GM–CSF–secreting pancreatic cancer cell vaccine (GVAX Pancreas) with live attenuated Listeria monocytogenes modified to express mesothelin (CRS-207) [ 79 ].…”

Section: Tumor Cell-derived Vaccinesmentioning

confidence: 99%

Engineered tumor cell-derived vaccines against cancer: The art of combating poison with poison

Zhang

Cui

Zhang

et al. 2023

Bioactive Materials

View full text Add to dashboard Cite

Section: Tumor Cell-derived Vaccinesmentioning

confidence: 99%

Engineered tumor cell-derived vaccines against cancer: The art of combating poison with poison

Zhang

Cui

Zhang

et al. 2023

Bioactive Materials

View full text Add to dashboard Cite

“…Tetanus-diphtheria toxoid (Td) is used as an antigen to precondition vaccination with the goal of promoting a more robust immune response [117,118]. Preclinical and clinical (NCT00639639) data show that a Td treatment prior to a DC vaccine (cytomegalovirus phosphoprotein 65, or CMV pp65) leads to improved DC migration, suppressed tumor growth, and prolonged survival (n = 12), which appeared dependent on the increased levels of the chemokine CCL3 [119].…”

Section: Adjuvant Therapiesmentioning

confidence: 99%

The Current Status, Challenges, and Future Potential of Therapeutic Vaccination in Glioblastoma

et al. 2023

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most common malignant primary brain tumor and confers a dismal prognosis. With only two FDA-approved therapeutics showing modest survival gains since 2005, there is a great need for the development of other disease-targeted therapies. Due, in part, to the profound immunosuppressive microenvironment seen in GBMs, there has been a broad interest in immunotherapy. In both GBMs and other cancers, therapeutic vaccines have generally yielded limited efficacy, despite their theoretical basis. However, recent results from the DCVax-L trial provide some promise for vaccine therapy in GBMs. There is also the potential that future combination therapies with vaccines and adjuvant immunomodulating agents may greatly enhance antitumor immune responses. Clinicians must remain open to novel therapeutic strategies, such as vaccinations, and carefully await the results of ongoing and future trials. In this review of GBM management, the promise and challenges of immunotherapy with a focus on therapeutic vaccinations are discussed. Additionally, adjuvant therapies, logistical considerations, and future directions are discussed.

show abstract

“…GVAX formulated with a STING agonist (STINGVAX) generated enhanced antitumor immunity compared to GVAX alone, and PD‐1 blockade further potentiated tumor control 93 . Linking GVAX with tetanus toxoid is being tested in a cervical cancer model 94 . A neoantigen‐based GVAX combination is being explored in colorectal cancer 95 .…”

Section: Future Of Gvaxmentioning

confidence: 99%

Whole tumor cell vaccines engineered to secrete GM‐CSF (GVAX)

Soiffer

Kooshesh

2021

ImmunoMedicine

View full text Add to dashboard Cite

Generation of immunity against cancer through vaccination has long been an elusive goal for tumor immunologists. Putative candidates for vaccination targets include oncofetal antigens, viral antigens, neoantigens, and differentiation antigens. The first attempts at cancer vaccination used injections of whole autologous tumor cells. However, these unmodified tumor cells did not engender a robust immune response. Subsequent efforts were focused at enhancing the immunogenicity of whole autologous tumor cell vaccines through genetic modification, often through virally mediated transduction of genes encoding immunostimulatory molecules. Of many immunostimulatory cytokines evaluated in the context of gene‐modified tumor cell vaccines, granulocyte–macrophage colony‐stimulating factor (GM‐CSF) emerged as the most potent in generating protective antitumor immunity. Vaccination using irradiated, GM‐CSF producing tumor cells (GVAX) consistently induced antitumor immunity across several experimental tumor models. The term GVAX can connote GM‐CSF secreting cell vaccines prepared with different vectors as well as vector targets including autologous tumor cells, allogeneic tumor cell lines, and bystander third party tumor cells lines. GVAX has been evaluated against solid tumors, hematologic malignancies, and in the context of hematopoietic stem cell transplantation. GVAX has been extensively studied in clinical trials, both alone and in conjunction with lymphodepleting chemotherapy, immune checkpoint inhibitors, and other vaccines.

show abstract

Combination Vaccination With Tetanus Toxoid and Enhanced Tumor-Cell Based Vaccine Against Cervical Cancer in a Mouse Model

Cited by 7 publications

References 41 publications

Engineered tumor cell-derived vaccines against cancer: The art of combating poison with poison

Engineered tumor cell-derived vaccines against cancer: The art of combating poison with poison

The Current Status, Challenges, and Future Potential of Therapeutic Vaccination in Glioblastoma

Whole tumor cell vaccines engineered to secrete GM‐CSF (GVAX)

Contact Info

Product

Resources

About